NNC 63-0532

NNC 63-0532 is a nociceptoid drug used in scientific research. It acts as a potent and selective agonist for the nociceptin receptor, also known as the ORL-1 (opiate receptor-like 1) receptor.[1][2]

NNC 63-0532

Clinical data
Other names	NNC 63-0532
Identifiers
IUPAC name methyl [8-(1-naphthylmethyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl)acetate
CAS Number	250685-44-0^Y
PubChem CID	9803475
ChemSpider	7979235
UNII	73663SY1DT
CompTox Dashboard (EPA)	DTXSID40397885
Chemical and physical data
Formula	C27H29N3O3
Molar mass	443.547 g·mol^−1
3D model (JSmol)	Interactive image
SMILES c3ccccc3N(CN(C2=O)CC(=O)OC)C2(CC4)CCN4Cc5c1ccccc1ccc5
InChI InChI=1S/C27H29N3O3/c1-33-25(31)19-29-20-30(23-11-3-2-4-12-23)27(26(29)32)14-16-28(17-15-27)18-22-10-7-9-21-8-5-6-13-24(21)22/h2-13H,14-20H2,1H3 Key:AQMPIDSGLFVVPL-UHFFFAOYSA-N
(verify)

The function of this receptor is still poorly understood, but it is thought to have roles in many disorders such as pain, drug addiction, development of tolerance to opioid drugs, and psychological disorders such as anxiety and depression. Research into the function of this receptor is an important focus of current pharmaceutical development, and selective agents such as NNC 63-0532 are essential for this work.[3]

References

1. Thomsen C, Hohlweg R (November 2000). "(8-Naphthalen-1-ylmethyl-4-oxo-1-phenyl-1,3,8-triaza-spiro[4. 5]dec-3-yl)-acetic acid methyl ester (NNC 63-0532) is a novel potent nociceptin receptor agonist". British Journal of Pharmacology. 131 (5): 903–8. doi:10.1038/sj.bjp.0703661. PMC 1572417. PMID 11053209.
2. Guerrini R, Carra' G, Calo' G, Trapella C, Marzola E, Rizzi D, et al. (June 2004). "Nonpeptide/peptide chimeric ligands for the nociceptin/orphanin FQ receptor: design, synthesis and in vitro pharmacological activity". The Journal of Peptide Research. 63 (6): 477–84. doi:10.1111/j.1399-3011.2004.00157.x. PMID 15175020.
3. Chiou LC, Liao YY, Fan PC, Kuo PH, Wang CH, Riemer C, Prinssen EP (January 2007). "Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications". Current Drug Targets. 8 (1): 117–35. doi:10.2174/138945007779315605. PMID 17266536.